The Russian pharmaceutical company "Geropharm" has created and registered insulin "Ringluzin". This was reported in the company's press service.
The new drug is the first Russian analogue of the French insulin "Apidra".
"Geropharm" registered a new insulin "Ringluzin" with the active substance glulisine, which is equal in strength to ordinary human insulin.
"Ringluzin" will be produced from the substance to the finished drug according to the principle of a full cycle at the Geropharm plants in the Moscow region and St. Petersburg. The volume of production will be determined based on demand.
Earlier www1.ru reported that new antibiotics will appear in Russia.
Read materials on the topic:
Stavropol scientists have developed nanoparticles to increase the effectiveness of antibiotics
First in the world: a gel for bone regeneration after gunshot wounds was invented in Russia
Russia has developed drugs for spinal muscular atrophy and Bekhterev's disease
Now on home
The service contains data on 45,000 fraudulent sites
The state has accelerated the introduction of unmanned solutions, integrating them into the real sector of the economy
Modernized engines may equip the Lada Azimut crossover
The price is 132 billion 265.8 million rubles
The manufacturer plans to strengthen its lineup of light commercial vehicles
The production of carbon fiber was organized in the shortest possible time
Electric vans will speed up the repair of urban transport infrastructure
Countries are working to synchronize regulations in the field of AI
The service's average daily audience is 55 million people
Stable Isomaterial Based on Metakaolin Has a Density Below 300 kg/m³
Re-identification quality improved twofold with new DynaMix method
Russians will be able to find out about debts online